TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06396286

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single rod
Description: surgical correction of severe adolescent idiopathic scoliosis with screws and a single rod.
Study: NCT04742543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SootheVR: AppliedVR, Los Angeles, California a head-mounted display
Description: For the study group, virtual reality content will be shown to the participant for the duration of the conization procedure through a head-mounted display, RelieVRTM. The default VR content for the trial will be swimming with dolphins or any other content chosen by the participant
Study: NCT06210984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low caffeine dose
Description: 2 mg/kg dose of caffeine in pill form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderate caffeine dose
Description: 5 mg/kg dose of caffeine in pill form

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 mg/kg dose of maltodextrin in pill form
Study: NCT06558708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR101 Injection
Description: Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR33 Injection
Description: Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Once daily
Study: NCT06400147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategy Training
Description: This intervention will use an adapted form of strategy training for people with neglect.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: This intervention will use a reflective listening protocol.
Study: NCT04887415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiratory Strength Training (RST) Program
Description: Participants will complete RST exercises 5 days per week by performing 5 sets of 5 repetitions of both expiratory and inspiratory muscle strength training (a total of 50 repetitions per day). Trainer devices will be calibrated to 50% of participants' maximum expiratory pressure (MEP) and maximum inspiratory pressure (MIP) as determined via respiratory assessment prior to and during the RST program.
Study: NCT06563115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (PEG)-BHD1028 Single Ascending Dose
Description: 4, 8, 16, 32, and 64 μg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (PEG)-BHD1028 Multiple Ascending Dose
Description: 8, 16, and 32 μg/Kg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent
Study: NCT05900713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dynamic neuromuscular stabilization training
Description: DNS methods demonstrated efficacy in improving global trunk stabilizing patterns with noted gains in extremity movement and strength

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance exercises plus diaphragmatic breathing
Description: The balance exercises is balance exercises while standing and walking The patient assume a semi-Fowler's position and perform diaphragmatic breathing.
Study: NCT05863936

Intervention type: DRUG
Group type: OTHER
Intervention: Methylprednisolone Injectable Suspension
Description: Methylprednisolone pulse therapy, total dose from 1500mg to 3000mg.
Study: NCT06558500

Intervention type: PROCEDURE
Intervention: Uterocervical angle
Description: With the patient in the lithotomy position and empty bladder, care was taken to avoid applying pressure to the cervix with the transvaginal probe. The cervix was aligned in the midline, and the endocervical canal was visualized throughout its length.During cervical measurement, care was taken to ensure that the internal os, external os, and entire endocervical canal were visible in the same image. With the endocervical canal, external os, and internal os linearly displayed on the screen, the angle between the endocervical canal, anterior and posterior uterine segment was measured using the ultrasound's angle measurement feature.For the measurement of the uterocervical angle, the first line of the angle was defined along the endocervical canal used for measuring cervical length, and the second line was drawn from the internal os along the anterior uterine segment for a minimum of two centimeters. The angle between these two lines was recorded as the uterocervical angle in the form.

Intervention type: PROCEDURE
Intervention: Uterocervical angle
Description: With the patient in the lithotomy position and empty bladder, care was taken to avoid applying pressure to the cervix with the transvaginal probe. The cervix was aligned in the midline, and the endocervical canal was visualized throughout its length.During cervical measurement, care was taken to ensure that the internal os, external os, and entire endocervical canal were visible in the same image. With the endocervical canal, external os, and internal os linearly displayed on the screen, the angle between the endocervical canal, anterior and posterior uterine segment was measured using the ultrasound's angle measurement feature.For the measurement of the uterocervical angle, the first line of the angle was defined along the endocervical canal used for measuring cervical length, and the second line was drawn from the internal os along the anterior uterine segment for a minimum of two centimeters. The angle between these two lines was recorded as the uterocervical angle in the form.
Study: NCT06562647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY001
Description: PBMC-derived anti-mesothelin Cheimeric Antigen Receptor macrophages
Study: NCT06080451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Diabetes and Hypertension Primary Care Model
Description: The intervention consists of five components that align with the World Health Organization Technical Package for Cardiovascular Disease Management in primary Health Care.~1. Training health workers on diabetes and hypertension treatment protocols~2. Team-based care and task sharing~3. Strengthening access to medications and diagnostics~4. Electronic medical record system and registry~5. Systems monitoring and feedback of key indicators

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Diabetes and Hypertension Primary Care Model - Providers
Description: The intervention consists of five components that align with the World Health Organization Technical Package for Cardiovascular Disease Management in primary Health Care.~1. Training health workers on diabetes and hypertension treatment protocols~2. Team-based care and task sharing~3. Strengthening access to medications and diagnostics~4. Electronic medical record system and registry~5. Systems monitoring and feedback of key indicators~Health care providers will administer this intervention to patient participants and will report on their experience.
Study: NCT05863936

Intervention type: DRUG
Group type: OTHER
Intervention: Belimumab Injection
Description: Belimumab at a dose of 10mg per kilogram at weeks 2, 4, and 6, and every 4 weeks for 24 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Immunosuppressive Agents
Description: 1. Mycophenolate Mofetil, oral, 1.0-1.5g per day;~2. Tacrolimus, oral, 2-4mg per day.
Study: NCT04950738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pess tack acupuncture
Description: Patients enrolled will receive intervention in a form of either press tack acupuncture needles or press tack placebos. Three total intervention sessions will be taken place on day 1,3,5 from patient's enrolment. Needles/placebos skin withdrawal will be done 48 hours after treatment by an acupuncture doctor or by a trained ICU nurne. In cases when a patient will be transferred from the ICU, the 3 study interventions will be continued in the new ward.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pess tack placebo
Description: pess tack stickers without a needle
Study: NCT06459973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous (IV) infusion
Description: YL205 is provided in the form of lyophilized powder under a strength of 160 mg/vial. Each vial should be reconstituted to 20 mg/mL. Prior to IV infusionSubjects will be treated with YL205 via intravenous (IV) infusion, once every 3 weeks (Q3W) as a treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous (IV) infusion
Description: YL205 is provided in the form of lyophilized powder under a strength of 160 mg/vial. Each vial should be reconstituted to 20 mg/mL. Prior to IV infusionSubjects will be treated with YL205 via intravenous (IV) infusion, once every 3 weeks (Q3W) as a treatment cycle
Study: NCT05495295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PhOx430
Description: The implementation of this cohort (Step 3) was decided by the Protocol Steering Committee (PSC) based on clinical and pharmacokinetic data obtained in Steps 1 and 2. Six patients will be enrolled, who will receive PhOx430 orally thrice a day (tid) at a -6-hour interval over 12 hours for 21 days, and then, starting from day 22, four times a day (qid) at a 4-hour interval over 12 hours, continuously in cycles of 21 days. PhOx430 will be taken in single doses of 1,200 mg to patients weighing ≥ 50 kg and of 600 mg to patients weighing \< 50 kg, with no requirement for a full or empty stomach. The first patient will be observed after treatment start for at least 21 days before enrolling the following two. After the third patient is observed for 21 days after treatment start, 3 additional patients will be enrolled without waiting time between them. If the daily dose tested with the tid schedule is not deemed safe, the flat dose will be tested twice a day (bid) at a 12-hour interval.
Study: NCT04786210

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fractional erbium:YAG-assisted drug delivery of 5-fluorouracil
Description: Split-scar fractional ablative erbium laser-assisted delivery of 50mg/mL of 5-fluorouracil solution to one half of the scar (4 treatments)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fractional erbium:YAG-assisted drug delivery of triamcinolone acetonide
Description: Split-scar fractional ablative erbium laser-assisted delivery of 10 mg/mL of triamcinolone acetonide solution to the other half of the scar (4 treatments)
Study: NCT06433115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lean (93%) Grass-Fed Beef
Description: The specified amount will be 4 oz. per day or 28 ounces per week for participants with an energy requirement of 2000 kcal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lean (93%) Grain-Fed Beef
Description: The specified amount will be 4 oz. per day or 28 ounces per week for participants with an energy requirement of 2000 kcal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plant-Based Meat
Description: Plant-based meat would be macronutrient matched to the same quantities of meat prescribed for a given energy level.
Study: NCT04814823

Intervention type: DEVICE
Intervention: Pulse oximeter
Description: OLV-4202 pulse oximeter (SW version: 01-11)
Study: NCT06251687

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transbronchial Cryobiopsy，TBLC
Description: Transbronchial lung cryobiopsy (TBLC) is a novel technique that has proved its diagnostic value in various diffuse parenchymal lung diseases

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transbronchial Lung Biopsy，TBLB
Description: Transbronchial lung biopsy (TBLB) is a relatively safe technique routinely employed by pulmonologists for the diagnosis of diffuse parenchymal lung disease
Study: NCT05712668

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative counseling
Description: Providers will review the diagnosis, surgical planning, risks/benefits/alternatives to surgery, post-operative care, and long term scope of care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative counseling
Description: Providers will review the diagnosis, surgical planning, risks/benefits/alternatives to surgery, post-operative care, and long term scope of care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asynchronous telemedicine
Description: An asynchronous video will be delivered by Mytonomy. This platform allows investigators to track user analytics relating to the time, frequency, or duration watched by the user.
Study: NCT06448377

Intervention type: PROCEDURE
Intervention: Videolaryngoscopy
Description: Situations in which the practitioner performs endotracheal intubation using a videolaryngoscope during airway intervention will be included in this group.

Intervention type: PROCEDURE
Intervention: Videolaryngoscopy
Description: Situations in which the practitioner performs endotracheal intubation using a videolaryngoscope during airway intervention will be included in this group.

Intervention type: PROCEDURE
Intervention: FOB
Description: Situations in which the practitioner performs endotracheal intubation using a fiberoptic bronchoscope during airway intervention will be included in this group.

Intervention type: PROCEDURE
Intervention: FOB
Description: Situations in which the practitioner performs endotracheal intubation using a fiberoptic bronchoscope during airway intervention will be included in this group.

Intervention type: PROCEDURE
Intervention: FOB+Aintree
Description: Situations in which the practitioner performs endotracheal intubation using a Fiberoptic intubation via LMA with aintree catheter during airway intervention will be included in this group.

Intervention type: PROCEDURE
Intervention: FOB+Aintree
Description: Situations in which the practitioner performs endotracheal intubation using a Fiberoptic intubation via LMA with aintree catheter during airway intervention will be included in this group.

Intervention type: PROCEDURE
Intervention: Classic intubation with laryngoscopy
Description: Situations in which the practitioner performs endotracheal intubation using a macintosh laryngoscope during airway intervention will be included in this group.

Intervention type: PROCEDURE
Intervention: Classic intubation with laryngoscopy
Description: Situations in which the practitioner performs endotracheal intubation using a macintosh laryngoscope during airway intervention will be included in this group.

Intervention type: PROCEDURE
Intervention: Others
Description: Cases in which intubation cannot be performed, those who are awakened from anesthesia, or those in whom a surgical method is used for airway access will be included in this group.

Intervention type: PROCEDURE
Intervention: Others
Description: Cases in which intubation cannot be performed, those who are awakened from anesthesia, or those in whom a surgical method is used for airway access will be included in this group.
Study: NCT04903860

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: total hip replacement with single use ancillary
Description: Comparison of the use of conventional ancillary reaming and single-use ancillary reaming material in total hip replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: total hip replacement with conventional ancillary
Description: Comparison of the use of conventional ancillary reaming and single-use ancillary reaming material in total hip replacement
Study: NCT05752448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POSTCare Survivorship transition process
Description: Survivorship coaching intervention
Study: NCT05237388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: One pill daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Baricitinib placebo pill
Study: NCT05485103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycols
Description: Take asol as total enteral nutrition, and take polyethylene glycols and glycerin enema as bowel preparations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycols
Description: Take asol as total enteral nutrition, and take polyethylene glycols and glycerin enema as bowel preparations
Study: NCT06459973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous (IV) infusion
Description: YL205 is provided in the form of lyophilized powder under a strength of 160 mg/vial. Each vial should be reconstituted to 20 mg/mL. Prior to IV infusionSubjects will be treated with YL205 via intravenous (IV) infusion, once every 3 weeks (Q3W) as a treatment cycle
Study: NCT05891171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB598
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB598
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB598
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB598
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB598
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB598
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB598
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB598
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered as specified in the treatment arm
Study: NCT04636034

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sphenopalatine Ganglion Block with Local Anesthetic
Description: Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sphenopalatine Ganglion Block with Placebo (Isotone NaCl)
Description: Block performed with bilaterally inserted q-tips with isotone NaCl

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-block with Placebo (Isotone NaCl)
Description: Block performed with bilaterally inserted q-tips with isotone NaCl. The q-tips are inserted a maximum of 3 cm into the nasopharynx thus not reaching the mucus above the ganglion.
Study: NCT05007509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine HIPRA 10
Description: One sentinel subject and 4 additional subjects will be assigned to COVID-19 vaccine HIPRA 10 µg
Study: NCT05303493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Camu Camu Capsules (Camu Camu powder encapsulated (500mg each) + ICI
Description: Evaluate the safety and tolerability of CC prebiotic in addition to ICI in patients with NSCLC and melanoma
Study: NCT05290220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07
Description: 1500 mg
Study: NCT05146492

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI with gadolinium contrast media injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: MRI with gadolinium contrast media injection
Study: NCT05450107

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Reduction Internal Fixation
Description: Surgical intervention by lag screw or plate fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cast immobilisation
Description: Cast immobilsation for a total of 6 weeks with gradual increase in weight bearing after 2 weeks
Study: NCT06180980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally.
Study: NCT05290220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07
Description: 1500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07
Description: 1500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04
Description: 15mg/kg
Study: NCT05646251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart Ultrasound
Description: A wand is placed on the chest to use soundwaves to make a picture of the heart and shows how the muscle and valves work. This helps with device placement.
Study: NCT05007509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine HIPRA 20
Description: One sentinel subject and 9 additional subjects will be assigned to COVID-19 vaccine HIPRA 20 µg
Study: NCT06185088

Intervention type: DEVICE
Group type: OTHER
Intervention: Coda® Balloon Catheters
Description: A balloon device that will be introduced into participants' intestine over a guide wire to test the radial stretch of the small bowel.

Intervention type: DEVICE
Group type: OTHER
Intervention: Double Balloon Endoscope (DBE)
Description: A balloon device that will be introduced retrograde through the ileostomy and the inter-balloon distance will be increased causing stretch on the intestine to test longitudinal stretch. The DBE will only be used if a participant tolerated the Coda® Balloon Catheter intervention.
Study: NCT05412576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride 2% Injection Solution
Description: Injectable

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride 2% Injection Solution
Description: Injectable

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride 2% Injection Solution
Description: Injectable

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: Injectable
Study: NCT05007509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine HIPRA 40
Description: One sentinel subject and 9 additional subjects will be assigned to COVID-19 vaccine HIPRA 40 µg

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Commercial COVID-19 vaccine
Description: One subject in cohort 1 and 2 subjects in Cohort 2 and 3 will be assigned to Commercial COVID-19 vaccine
Study: NCT06534996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCD-2101
Description: Tradictional Chinese Medicine formula (SCD-2101)
Study: NCT06227858

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Safr'Inside supplement (Activ'Inside, SAS)
Description: Dietary supplementation will be taken in addition to habitual diet of the patients

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plcebo
Description: Placebo capsule (matched to the experimental intervention in terms of colours and taste, without the active compounds saffron)